Effect of incadronate on proliferation of mesenchymal tumor cells with or without activated Ras mutation

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 4, 2005, Pages 617-624

  Kawashima, H ^a,a   Ogose, Akira ^a   Hotta, T ^a   Ito, T ^a   Endo, N ^a   Tamura, K ^b   Nakano, K ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Antitumor effect; Bisphosphonate; Incadronate; Mesenchymal tumor cell; Mevalonate pathway; Ras

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GERANYLGERANYL PYROPHOSPHATE; INCADRONIC ACID; MEVALONIC ACID; TRITIUM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HT 1080; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; FIBROSARCOMA; GENE MUTATION; HUMAN; HUMAN CELL; MESENCHYMOMA; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTORADIOGRAPHY; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; DIPHOSPHONATES; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS; MESENCHYMOMA; MEVALONIC ACID; MUTATION; POLYMERASE CHAIN REACTION;

EID: 31344440533     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Shipman C.M., Croucher P.I., Russell R.G.G, Helfrich M.H., Rogers M.J.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58:5294-5297, 1998.
2. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Luekemia 12:220-229, 1998.
3. Van der Pluijm G., Vloedgraven H., Van Beek E., Van der Wee-Pals L., Löwik C., Papapoulos S.: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Investig. 98:698-705, 1996.
4. Boissier S., Magnetto S., Frappart L. et al.: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57:3890-3894, 1997.
5. Sasaki A., Boyce B.F., Story B. et al.: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551-3557, 1995.
6. Berenson J.R., Lichtenstein A., Porter L. et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 16:593-602, 1998.
7. McCloskey E.V., MacLennan I.C.M., Drayson M.T., Chapman C., Dunn J., Kanis J.A.: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br. J. Haematol. 100:317-325, 1998.
8. Diel I.J., Solomayer E.F., Costa S.D. et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339:357-363, 1998.
9. Sonnemann J., Eckerzogt V, Truckenbrod B., Boos J., Winkelmann W., Van Valen F.: The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12:459-465, 2001.
10. Mackie P.S., Fisher J.L., Zhou H., Choong P.F.: Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer 84:951-958, 2001.
11. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:581-589, 1998.
12. Maillet N.W., Robinson R.A., Burgert L.J.: Genomic alterations in sarcomas: a histologic correlative study with use of oncogene panels. Mod. Pathol. 5:410-414, 1992.
13. Chakraborty A.K., Cichutek K., Duesberg P.H.: Transforming function of proto-ras genes depends on heterologous promoters and is enhanced by specific point mutations. Proc. Natl. Acad. Sci. USA. 88:2217-2221, 1991.
14. Tassone P., Tagliaferri P., Viscomi C., Palmieri C., Caraglia M., D'Alessandro A., Galea E., Goel A., Abbruzzese A., Boland C.R., Venuta S.: Zoledronic acid induces aniproloferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 88; 1971-1978, 2003.
15. Hotta T., Motoyama T., Watanabe H.: Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol. Jpn. 42:595-603, 1992.
16. Kunisada T., Miyazaki M., Mihara K., et al.: A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int. J. Cancer. 77:854-859, 1998.
17. Sasaki K., Mizusawa H., Ishidate M.: Isolation and characterization of ras-transfected BALB/3T3 clone showing morphological transformation by 12-O-tetradecanoyl-phorbol-13-acetate. Jpn. J. Cancer Res. 79:921-930, 1988.
18. Plattner R., Anderson M.J., Sato K.Y., Fasching C.L., Der C.J., Stanbridge E.J.: Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc. Natl. Acad. Sci. USA. 93:6665-6670, 1996.
19. Rogers M.J., Brown R.J., Hodkin V, Blackburn G.M., Russell R.G. and Watts D.J.: Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 224: 863-869, 1996.
20. Gibbs J.B., Oliff A.: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37:143-166, 1997.
21. Carloni G., Paterson H., Marcel M. et al.: N-ras dependent revertant phenotype in human HT1080 fibrosarcoma cells is associated with loss of proliferation within normal tissues and expression of an adult membrane antigenic phenotype. Oncogene 4:873-880, 1989.
22. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K. W.: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82:1459-1468, 2000.
23. Komori A., Yatsunami J., Suganuma M. et al.: Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res. 53:1982-1985, 1993.
24. Stephan J.J., Alenfeld F., Boivin G., Feven J.H., Lakatos P.: Mechanism of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr. Regul. 37:225-238, 2003.
25. Mönkkönen J., Koponen H., Ylitalo P.: Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol. 66:294-298, 1990.